GlassScriptPhysician profile
Antonio Rosado
NPI 1295765659
$2,872.47
in general payments reported to CMS, 2019-2025
31 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $353 · 2021: $307 · 2022: $287 · 2023: $370 · 2024: $265 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127 · Consulting Fee: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.82 |
| Consulting Fee | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $392.58 | 2019-2025 | |
| Amgen INC. | $275.55 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $215.86 | 2019-2024 | Watchman Flx |
| Shockwave Medical, INC | $195.91 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $189.92 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $176.11 | 2019-2024 | Farxiga, Brilinta |
| Amarin Pharma, INC. | $154.61 | 2019-2023 | |
| Heartflow, INC. | $145.96 | 2025 | |
| Janssen Pharmaceuticals, INC | $135.35 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $122.11 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $115.82 | 2019-2023 | |
| Pfizer INC. | $112.00 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $103.09 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.14 | 2019-2022 | |
| Esperion Therapeutics, INC. | $72.12 | 2025 | Nexletol |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $71.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $36.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.26 | 2024 | Jardiance |
| Bridgebio Pharma, INC. | $25.23 | 2025 | Attruby |
| Abbott Laboratories | $23.43 | 2020 | |
| Impulse Dynamics (USA) INC. | $21.09 | 2023 | Optimizer |
| Teleflex LLC | $20.63 | 2025 | Guideliner |
| Kiniksa Pharmaceuticals, LTD. | $19.59 | 2023 | Arcalyst |
| Philips North America LLC | $18.49 | 2023 | |
| Merck Sharp & Dohme LLC | $17.29 | 2023 | Verquvo |
| Arbor Pharmaceuticals, INC. | $15.38 | 2019 | |
| Baxter Healthcare | $15.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Siemens Medical Solutions USA, INC. | $14.45 | 2025 | Symbia_evo |
| Medicure Pharma INC. | $13.20 | 2023 | Zypitamag |
| Kowa Pharmaceuticals America, INC. | $13.18 | 2020 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Rosado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.